FDA Grants Emergency Order Over COVID

(FreedomBeacon.com)- The Food and Drug Administration just granted emergency use authorization for a new COVID-19 antibody drug that was created by GlaxoSmithKline, otherwise known as “GSK.” The antibody drug is similar to the antibody cocktail taken by former President Donald Trump last year when he was infected by the COVID-19 virus, which ultimately assisted him in his extremely quick recovery during the final weeks of the presidential election campaign.

The drug, known as Sotrovimab, is an “investigational monoclonal antibody therapy” that has been authorized for treating mild to moderate COVID in adults as well as children over the age of 12. The emergency use authorization means that it can be administered to anybody who is at risk of suffering from severe COVID symptoms.

It will not be used on patients who have been hospitalized following a COVID infection, nor will it be given to anybody going through oxygen therapy, as those with serious symptoms are not likely to benefit from the effects of the drug in the same way.

GSK worked with Vir Biotechnology on the new drug, and they both issued a statement saying that it will be available for American patients in the next few weeks. They also added that they plan to achieve a full approval for the drug treatment in the second half of this year.

The drug is reportedly capable of reducing the risk of death or hospitalization in 85% of those who take it, following a trial involving 868 COVID patients.

Naturally, the drug does have some side effects, with the worst reported including mild or severe rashes and diarrhea.

Lab studies have shown that the drug is able to maintain activity against all variants of COVID known at present. It utilizes monoclonal antibodies that help the body fight the virus when full antibodies are not present. These monoclonal antibodies are proteins made in a lab that mimic the effect of real antibodies.

It’s great news for those suffering from mild effects of the virus, but the fact that it may only achieve full certification by the end of the year is yet another indication that this virus isn’t going away fully any time soon.